How many drugs treat Nephroblastoma?

Drug Landscape tracks 10 marketed treatments for Nephroblastoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nephroblastoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nephroblastoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nephroblastoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nephroblastoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Cosmegen	DACTINOMYCIN	Recordati	Actinomycin [EPC]	DNA	1964-01-01
Oncovin	vincristine	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Vincristin	Vincristin	Arbeitsgemeinschaft medikamentoese Tumortherapie		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1
Hydroxydaunorubicin	Hydroxydaunorubicin	University of Colorado, Denver		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunomycin	Hydroxydaunomycin	Weill Medical College of Cornell University		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Oncovin	Oncovin	University of Colorado, Denver		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Nephroblastoma
University of Colorado, Denver · 2 drugs in Nephroblastoma
Pfizer Inc. · 2 drugs in Nephroblastoma
Recordati · 1 drug in Nephroblastoma
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 drug in Nephroblastoma
Weill Medical College of Cornell University · 1 drug in Nephroblastoma
Chipscreen Biosciences, Ltd. · 1 drug in Nephroblastoma
Johann Wolfgang Goethe University Hospital · 1 drug in Nephroblastoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nephroblastoma:

Cite this brief

Drug Landscape (2026). Nephroblastoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nephroblastoma. Accessed 2026-06-10.

Nephroblastoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing